Altered Striatal Dopamine Levels in Parkinson's Disease VPS35 D620N

Total Page:16

File Type:pdf, Size:1020Kb

Altered Striatal Dopamine Levels in Parkinson's Disease VPS35 D620N Vanan et al. Mol Brain (2020) 13:164 https://doi.org/10.1186/s13041-020-00704-3 RESEARCH Open Access Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice Sarivin Vanan1† , Xiaoxia Zeng1†, Sook Yoong Chia1, Katarina Varnäs2, Mei Jiang1, Ke Zhang1, Wuan Ting Saw3, Parasuraman Padmanabhan4, Wei‑Ping Yu5,6, Zhi‑Dong Zhou3,7, Christer Halldin2,4, Balázs Gulyás2,4, Eng‑King Tan3,7,8* and Li Zeng1,7,9* Abstract Vacuolar protein sorting 35 (VPS35) is a major component of the retromer complex that mediates the retrograde transport of cargo proteins from endosomes to the trans‑Golgi network. Mutations such as D620N in the VPS35 gene have been identifed in patients with autosomal dominant Parkinson’s disease (PD). However, it remains poorly understood whether and how VPS35 defciency or mutation contributes to PD pathogenesis; specifcally, the studies that have examined VPS35 thus far have difered in results and methodologies. We generated a VPS35 D620N mouse model using a Rosa26‑based transgene expression platform to allow expression in a spatial manner, so as to better address these discrepancies. Here, aged (20‑months‑old) mice were frst subjected to behavioral tests. Subsequently, DAB staining analysis of substantia nigra (SN) dopaminergic neurons with the marker for tyrosine hydroxylase (TH) was performed. Next, HPLC was used to determine dopamine levels, along with levels of its two metabolites, 3,4‑dihy‑ droxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), in the striatum. Western blotting was also performed to study the levels of key proteins associated with PD. Lastly, autoradiography (ARG) evaluation of [ 3H]FE‑PE2I binding to the striatal dopamine transporter DAT was carried out. We found that VPS35 D620N Tg mice displayed a signifcantly higher dopamine level than NTg counterparts. All results were then compared with that of current VPS35 studies to shed light on the disease pathogenesis. Our model allows future studies to explicitly control spatial expression of the transgene which would generate a more reliable PD phenotype. Keywords: Parkinson’s disease, VPS35 D620N, Striatal dopamine, Transgenic mice, Behavioral assay Background 80 years old and older [1]. Individuals with PD display Parkinson’s disease (PD) is one of the most common neu- motor symptoms such as resting tremor, bradykinesia, rodegenerative disorders globally, with the prevalence rigidity and postural instability [2]. Nonmotor symptoms of PD being reported to be approximately 1% in people may also be present, including cognitive impairment, 60 years old and older, and increasing to 1–3% in those mood disorders and difculty swallowing [3]. Although PD is largely an idiopathic disease, approximately 5 to 10% of cases are hereditary, with mutations in at least 13 *Correspondence: [email protected]; [email protected] genes being shown to cause familial PD; one of these is †Sarivin Vanan and Xiaoxia Zeng contributed equally to this work 1 Neural Stem Cell Research Lab, Research Department, National the vacuolar protein sorting 35 (VPS35, PARK17) gene Neuroscience Institute, Singapore 308433, Singapore [4, 5]. 3 Department of Research, National Neuroscience Institute, 11 Jalan Tan In previous exome sequencing studies, the D620N Tock Seng, Singapore 308433, Singapore Full list of author information is available at the end of the article mutation in VPS35 has been identifed as being © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Vanan et al. Mol Brain (2020) 13:164 Page 2 of 15 pathogenic for late-onset autosomal dominant PD in allowed us to study a mouse model in which there is spa- numerous families from various ethnic backgrounds [6, tial expression of the transgene in a physiologically rel- 7]. Te VPS35 gene encodes a key component of the ret- evant manner, which would generate a more reliable PD romer complex, which operates by packaging particular phenotype. Furthermore, we analyzed mice at an even endosomal cargoes into tubules and vesicles and then older age (20-months-old) to reveal age-related neurode- transporting these cargoes either to the trans-Golgi net- generation in Parkinson’s disease. work or to the plasma membrane [8]. Te retromer con- sists of two subprotein complexes: the cargo-selective Results complex, which contains a VPS35-VPS29-VPS26 trimer Generation of VPS35 D620N transgenic mice [9], and the membrane deformation complex, which con- Te generation of this VPS35 D620N mouse model sists of a sorting nexin dimer [10]. started with the microinjection of the entire VPS35- Te upregulation of wild-type (WT) human VPS35 D620N construct into pronuclei fertilized oocytes of has been shown to rescue α-synuclein-induced neu- pseudopregnant C57BL/6j females. After establish- rodegeneration, and the knockdown of endogenous ing germ-line transmission, two founder lines were VPS35 resulted in substantial neuronal loss in the hip- then backcrossed to produce homozygous founders pocampus of α-synuclein transgenic (Tg) mice. Tese (C57BL/6J-LSL-VPS35 D620N/D620N). Te VPS35-D620N fndings suggest that VPS35 is able to functionally antag- construct itself was inserted into the mouse Rosa26 locus onize α-synuclein-mediated neurodegeneration [11]. under the control of an exogenous CAGGS promoter Tis result is also supported by the fndings of Linhart’s (rather than the endogenous Rosa26 promoter). A strong study, in which they determined that the overexpression transcriptional termination signal sequence fanked by of VPS35 signifcantly protects against locomotor defcits two loxP sites was inserted between the promoter and observed in mutant LRRK2 fies, while knocking down the transgene coding sequence, which is, in turn, directly the expression of VPS35 in dopaminergic neurons causes adjacent to a HA tag sequence (Fig. 1A). Under these signifcant locomotor impairment [12]. Together, these circumstances (i.e., in the absence of Cre recombinase), fndings indicate that VPS35 plays a protective role in the transgene coding sequence is not expressed due to regard to dopamine neurons. However, other studies have the presence of the transcriptional termination signal also presented evidence that VPS35 can have an adverse sequence. However, in the presence of Cre recombi- efect. In rat primary cortical cultures, the overexpression nase, the transcriptional termination signal sequence is of human WT or VPS35 D620N induces neuronal cell excised, which leads to the derepression of the transgene. death, while in a novel viral-mediated gene transfer rat Since the homozygous founder line (C57BL/6J-LSL- model, the expression of human WT or VPS35 D620N VPS35D620N/D620N) bearing the VPS35 D620N allele can induces substantial degeneration and axonal pathology in only be expressed in the brain after Cre-mediated exci- substantia nigra (SN) dopaminergic neurons [13]. sion of the STOP cassette, the homozygous founder lines Hence, the generation of genetically engineered rodent were crossed with C57BL/6J mice (National University of models with the VPS35 D620 mutation could not only Singapore Comparative Medicine Centre) frst to obtain overcome the problems inherent in using viral transfec- hemizygous mice (C57BL/6J-LSL-VPS35D620N/−). Sub- tion but could also provide a crucial tool for understand- sequently, these hemizygous mice were crossed with the ing the pathophysiology of VPS35. Ishizu’s group frst B6.Cg-Tg(Nes-cre)1kln/J mouse strain purchased from investigated the VPS35 D620N gene in vivo using D620N Jackson Laboratories [15]. Te VPS35 D620N transgene knock-in (KI) mice, and they found neither homozy- can now be specifcally expressed in the central and gous nor heterozygous VPS35 D620N KI mice had suf- peripheral nervous systems. More importantly, this fered premature death or had developed clear signs of allows transgenic expression in brain tissue. To confrm neurodegeneration at up to 15 months of age [14]. Tese the success of the transgene sequence insertion, PCR results suggest that the VPS35 D620N allele is still func- amplifcation was performed using designated primers, tional and does not cause obvious dopamine neuron loss; followed by electrophoresis on a 2% (w/v) agarose gel. All they also suggest that the VPS35 D620N allele is a par- VPS35 D620N transgenic mice showed a clear band at tial loss-of-function allele, and genetic predisposition and 525 bp, while nontransgenic (NTg) mice had no band. All age-related alterations in the nigrostriatal dopamine sys- mice used in this study (both VPS35 D620N NTg and Tg) tem cooperatively infuence the pathogenesis of VPS35. were Nestin cre positive (Fig. 1b). Here, we generated a novel VPS35 D620N transgenic mouse line by integrating a single copy of a transgene Characterization of transgenic VPS35 D620N mice (VPS35-D620N) into the mouse Rosa26 locus under the Given that VPS35 D620N mice were crossed with Nes- control of an exogenous CAGGS promoter. Tis strategy tin cre mice, VPS35 D620N (detected by HA antibody) Vanan et al. Mol Brain (2020) 13:164 Page 3 of 15 Fig.
Recommended publications
  • DF2589-MUL1 Antibody
    Affinity Biosciences website:www.affbiotech.com order:[email protected] MUL1 Antibody Cat.#: DF2589 Concn.: 1mg/ml Mol.Wt.: 38 kDa Size: 50ul,100ul,200ul Source: Rabbit Clonality: Polyclonal Application: WB 1:500-1:2000, ELISA(peptide) 1:20000-1:40000 *The optimal dilutions should be determined by the end user. Reactivity: Human,Mouse,Rat Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific). Specificity: MUL1 Antibody detects endogenous levels of total MUL1. Immunogen: A synthesized peptide derived from human MUL1, corresponding to a region within the internal amino acids. Uniprot: Q969V5 Description: Exhibits weak E3 ubiquitin-protein ligase activity, but preferentially acts as a SUMO E3 ligase at physiological concentrations. Plays a role in the control of mitochondrial morphology. Promotes mitochondrial fragmentation and influences mitochondrial localization. Inhibits cell growth. When overexpressed, activates JNK through MAP3K7/TAK1 and induces caspase-dependent apoptosis. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. Storage Condition and Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM Buffer: NaCl, 0.02% sodium azide and 50% glycerol. Western blot analysis of extracts from various samples, using MUL1 Antibody. Lane 1: Rat liver, blocked with antigen-specific peptides, Lane 2: Rat liver, Lane 3: Hela cells. 1 / 2 Affinity Biosciences website:www.affbiotech.com order:[email protected] Western blot analysis of MUL1 expression in A431 whole cell lysates ,The lane on the left was treated with the antigen- specific peptide.
    [Show full text]
  • MUL1 Polyclonal Antibody Catalog Number PA5-29550 Product Data Sheet
    Lot Number: TE2564971L Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 thermofisher.com/contactus MUL1 Polyclonal Antibody Catalog Number PA5-29550 Product Data Sheet Details Species Reactivity Size 100 µL Tested species reactivity Human Host / Isotype Rabbit IgG Tested Applications Dilution * Class Polyclonal Immunocytochemistry (ICC) 1:100-1:1000 Type Antibody Immunofluorescence (IF) 1:100-1:1000 Recombinant fragment Immunohistochemistry (Paraffin) Immunogen corresponding to a region within 1:100-1:1000 amino acids 1 and 352 of Human (IHC (P)) MUL1 Western Blot (WB) 1:500-1:3000 Conjugate Unconjugated * Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their Form Liquid own experiment using appropriate negative and positive controls. Concentration 1.34mg/ml Purification Antigen affinity chromatography Storage Buffer PBS, pH 7, with 1% BSA, 20% glycerol Contains 0.025% Proclin 300 Storage Conditions -20° C, Avoid Freeze/Thaw Cycles Product Specific Information PA5-29550 targets MUL1 in IF and WB applications and shows reactivity with Human samples. The PA5-29550 immunogen is recombinant fragment corresponding to a region within amino acids 1 and 352 of Human MUL1. Background/Target Information E3 ubiquitin-protein ligase that plays a role in the control of mitochondrial morphology. Promotes mitochondrial fragmentation and influences mitochondrial localization. Inhibits cell growth. When overexpressed, activates JNK through MAP3K7/TAK1 and induces caspase-dependent apoptosis. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates.
    [Show full text]
  • Amyloid Β-Peptide Increases Mitochondria-Endoplasmic
    cells Article Amyloid β-Peptide Increases Mitochondria-Endoplasmic Reticulum Contact Altering Mitochondrial Function and Autophagosome Formation in Alzheimer’s Disease-Related Models Nuno Santos Leal 1,*, Giacomo Dentoni 1 , Bernadette Schreiner 1 , Luana Naia 1, Antonio Piras 1, Caroline Graff 1, Antonio Cattaneo 2, Giovanni Meli 2 , Maho Hamasaki 3, Per Nilsson 1 and Maria Ankarcrona 1,* 1 Division of Neurogeriatrics, Department of Neurobiology, Care Science and Society, Karolinska Institutet, BioClinicum J9:20, Visionsgatan 4, 171 64 Solna, Sweden; [email protected] (G.D.); [email protected] (B.S.); [email protected] (L.N.); [email protected] (A.P.); caroline.graff@ki.se (C.G.); [email protected] (P.N.) 2 European Brain Research Institute (EBRI), Viale Regina Elena 295, 00161 Roma, Italy; [email protected] (A.C.); [email protected] (G.M.) 3 Department of Genetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; [email protected] * Correspondence: [email protected] (N.S.L.); [email protected] (M.A.); Tel.: +44-122-333-4390 (N.S.L.); +46-852-483-577 (M.A.) Received: 23 October 2020; Accepted: 25 November 2020; Published: 28 November 2020 Abstract: Recent findings have shown that the connectivity and crosstalk between mitochondria and the endoplasmic reticulum (ER) at mitochondria–ER contact sites (MERCS) are altered in Alzheimer’s disease (AD) and in AD-related models. MERCS have been related to the initial steps of autophagosome formation as well as regulation of mitochondrial function. Here, the interplay between MERCS, mitochondria ultrastructure and function and autophagy were evaluated in different AD animal models with increased levels of Aβ as well as in primary neurons derived from these animals.
    [Show full text]
  • The Mitochondrial Kinase PINK1 in Diabetic Kidney Disease
    International Journal of Molecular Sciences Review The Mitochondrial Kinase PINK1 in Diabetic Kidney Disease Chunling Huang * , Ji Bian , Qinghua Cao, Xin-Ming Chen and Carol A. Pollock * Kolling Institute, Sydney Medical School, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2065, Australia; [email protected] (J.B.); [email protected] (Q.C.); [email protected] (X.-M.C.) * Correspondence: [email protected] (C.H.); [email protected] (C.A.P.); Tel.: +61-2-9926-4784 (C.H.); +61-2-9926-4652 (C.A.P.) Abstract: Mitochondria are critical organelles that play a key role in cellular metabolism, survival, and homeostasis. Mitochondrial dysfunction has been implicated in the pathogenesis of diabetic kidney disease. The function of mitochondria is critically regulated by several mitochondrial protein kinases, including the phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1). The focus of PINK1 research has been centered on neuronal diseases. Recent studies have revealed a close link between PINK1 and many other diseases including kidney diseases. This review will provide a concise summary of PINK1 and its regulation of mitochondrial function in health and disease. The physiological role of PINK1 in the major cells involved in diabetic kidney disease including proximal tubular cells and podocytes will also be summarized. Collectively, these studies suggested that targeting PINK1 may offer a promising alternative for the treatment of diabetic kidney disease. Keywords: PINK1; diabetic kidney disease; mitochondria; mitochondria quality control; mitophagy Citation: Huang, C.; Bian, J.; Cao, Q.; 1. Introduction Chen, X.-M.; Pollock, C.A.
    [Show full text]
  • Efficacy and Mechanistic Evaluation of Tic10, a Novel Antitumor Agent
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2012 Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Joshua Edward Allen University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Oncology Commons Recommended Citation Allen, Joshua Edward, "Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent" (2012). Publicly Accessible Penn Dissertations. 488. https://repository.upenn.edu/edissertations/488 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/488 For more information, please contact [email protected]. Efficacy and Mechanisticv E aluation of Tic10, A Novel Antitumor Agent Abstract TNF-related apoptosis-inducing ligand (TRAIL; Apo2L) is an endogenous protein that selectively induces apoptosis in cancer cells and is a critical effector in the immune surveillance of cancer. Recombinant TRAIL and TRAIL-agonist antibodies are in clinical trials for the treatment of solid malignancies due to the cancer-specific cytotoxicity of TRAIL. Recombinant TRAIL has a short serum half-life and both recombinant TRAIL and TRAIL receptor agonist antibodies have a limited capacity to perfuse to tissue compartments such as the brain, limiting their efficacy in certain malignancies. To overcome such limitations, we searched for small molecules capable of inducing the TRAIL gene using a high throughput luciferase reporter gene assay. We selected TRAIL-inducing compound 10 (TIC10) for further study based on its induction of TRAIL at the cell surface and its promising therapeutic index. TIC10 is a potent, stable, and orally active antitumor agent that crosses the blood-brain barrier and transcriptionally induces TRAIL and TRAIL-mediated cell death in a p53-independent manner.
    [Show full text]
  • The Contributions of Microglial Vps35 to Adult Hippocampal Neurogenesis and Neurodegenerative Disorders
    THE CONTRIBUTIONS OF MICROGLIAL VPS35 TO ADULT HIPPOCAMPAL NEUROGENESIS AND NEURODEGENERATIVE DISORDERS By Joanna Ruth Erion Submitted to the Faculty of the Graduate School of Augusta University in partial fulfillment of the Requirements of the Degree of Doctor of Philosophy April 2017 COPYRIGHT© 2017 by Joanna Ruth Erion THE CONTRIBUTIONS OF MICROGLIAL VPS35 TO ADULT HIPPOCAMPAL NEUROGENESIS AND NEURODEGENERATIVE DISORDERS This thesis/dissertation is submitted by Joanna Ruth Erion and has been examined and approved by an appointed committee of the faculty of the Graduate School of Augusta University. The signatures which appear below verify the fact that all required changes have been incorporated and that the thesis/dissertation has received final approval with reference to content, form and accuracy of presentation. This thesis/dissertation is therefore in partial fulfillment of the requirements for the degree of Doctor of Philosophy). ___________________ __________________________________ Date Major Advisor __________________________________ Departmental Chairperson __________________________________ Dean, Graduate School ACKNOWLEDGEMENTS I will be forever grateful to my mentor, Dr. Wen-Cheng Xiong, for welcoming me into her laboratory and providing me with the honor and opportunity to work under her astute leadership. I have learned many valuable lessons under her guidance, all of which have enabled me to grow as both a student and a scientist. It was with her erudite guidance and suggestions that I was able to examine aspects of my investigations that I had yet to consider and ask questions that would not have otherwise occurred to me. I would also like to thank Dr. Lin Mei for contributing not only his laboratory and resources to my endeavors, but also his guidance and input into my investigations, providing me with additional avenues for directing my efforts.
    [Show full text]
  • 2328.Full.Pdf
    Altered interplay between endoplasmic reticulum and mitochondria in Charcot–Marie–Tooth type 2A neuropathy Nathalie Bernard-Marissala,b,1, Gerben van Hamerenc, Manisha Junejad,e, Christophe Pellegrinof, Lauri Louhivuorig, Luca Bartesaghih,i, Cylia Rochata, Omar El Mansoura, Jean-Jacques Médardh,i, Marie Croisierj, Catherine Maclachlanj, Olivier Poirotk, Per Uhléng, Vincent Timmermand,e, Nicolas Tricaudc, Bernard L. Schneidera,1,2, and Roman Chrasth,i,1,2 aBrain Mind Institute, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; bMarseille Medical Genetics, INSERM, Aix-Marseille Univ, 13385 Marseille, France; cINSERM U1051, Institut des Neurosciences de Montpellier, Université de Montpellier, 34295 Montpellier, France; dPeripheral Neuropathy Research Group, Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium; eInstitute Born Bunge, 2610 Antwerp, Belgium; fInstitut de Neurobiologie de la Méditerranée, INSERM, Aix-Marseille Univ, 13009 Marseille, France; gDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; hDepartment of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; iDepartment of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; jCentre of Interdisciplinary Electron Microscopy, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland; and kDepartment of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland Edited by Stephen T. Warren, Emory University School of Medicine, Atlanta, GA, and approved December 14, 2018 (received for review June 26, 2018) Mutations in the MFN2 gene encoding Mitofusin 2 lead to the axons (8). However, the long-term progression of the disease and development of Charcot–Marie–Tooth type 2A (CMT2A), a domi- the mechanisms underlying motor and/or sensory dysfunction nant axonal form of peripheral neuropathy. Mitofusin 2 is local- have not been fully characterized in this model.
    [Show full text]
  • Protein Kinases and Parkinson's Disease
    International Journal of Molecular Sciences Review Protein Kinases and Parkinson’s Disease Syed Jafar Mehdi 1, Hector Rosas-Hernandez 2, Elvis Cuevas 2, Susan M. Lantz 2, Steven W. Barger 1,3, Sumit Sarkar 2, Merle G. Paule 2, Syed F. Ali 2 and Syed Z. Imam 1,2,* 1 Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; [email protected] (S.J.M.); [email protected] (S.W.B.) 2 Division of Neurotoxicology, National Center for Toxicological Research/US Food and Drug Administration, Jefferson, AR 72079, USA; [email protected] (H.R.-H.); [email protected] (E.C.); [email protected] (S.M.L.); [email protected] (S.S.); [email protected] (M.G.P.); [email protected] (S.F.A.) 3 Geriatric Research Education and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA * Correspondence: [email protected]; Tel.: +1-870-543-7989; Fax: +1-870-543-7745 Academic Editor: Katalin Prokai-Tatrai Received: 30 May 2016; Accepted: 1 September 2016; Published: 20 September 2016 Abstract: Currently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson’s disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinically for other indications. Kinase inhibitors represent a family of popular molecules for the treatment and prevention of various cancers, and have emerged as strong candidates for such repurposing because numerous serine/threonine and tyrosine kinases have been implicated in the pathobiology of Parkinson’s disease.
    [Show full text]
  • Parkinson's Disease Causative Mutation in Vps35 Disturbs Tetherin
    cells Article Parkinson’s Disease Causative Mutation in Vps35 Disturbs Tetherin Trafficking to Cell Surfaces and Facilitates Virus Spread Yingzhuo Ding 1,†, Yan Li 1,† , Gaurav Chhetri 1 , Xiaoxin Peng 1, Jing Wu 1, Zejian Wang 1, Bo Zhao 1 , Wenjuan Zhao 1 and Xueyi Li 1,2,* 1 School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China; [email protected] (Y.D.); [email protected] (Y.L.); [email protected] (G.C.); [email protected] (X.P.); [email protected] (J.W.); [email protected] (Z.W.); [email protected] (B.Z.); [email protected] (W.Z.) 2 Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA * Correspondence: [email protected] or [email protected] † These authors contributed equally to this work. Abstract: Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, characterized by progressive loss of dopaminergic neurons in the substantia nigra, intraneuronal deposition of misfolded proteins known as Lewy bodies, and chronic neuroinflammation. PD can arise from monogenic mutations, but in most cases, the etiology is unclear. Viral infection is gaining increasing attentions as a trigger of PD. In this study, we investigated whether the PD-causative Citation: Ding, Y.; Li, Y.; Chhetri, G.; 620 aspartate (D) to asparagine (N) mutation in the vacuolar protein sorting 35 ortholog (Vps35) Peng, X.; Wu, J.; Wang, Z.; Zhao, B.; precipitated herpes simplex virus (HSV) infection. We observed that ectopic expression of Vps35 Zhao, W.; Li, X. Parkinson’s Disease significantly reduced the proliferation and release of HSV-1 virions; the D620N mutation rendered Causative Mutation in Vps35 Vps35 a partial loss of such inhibitory effects.
    [Show full text]
  • Retromer Deficiency Observed in Alzheimer's Disease Causes
    Retromer deficiency observed in Alzheimer’s disease causes hippocampal dysfunction, neurodegeneration, and A␤ accumulation Alim Muhammad*, Ingrid Flores*, Hong Zhang*†, Rui Yu*, Agnieszka Staniszewski*†, Emmanuel Planel*†, Mathieu Herman*†, Lingling Ho‡, Robert Kreber‡, Lawrence S. Honig*§, Barry Ganetzky‡¶, Karen Duff*†, Ottavio Arancio*†, and Scott A. Small*§¶ *Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and Departments of §Neurology and †Pathology, Columbia University College of Physicians and Surgeons, New York, NY 10032; and ‡Laboratory of Genetics, University of Wisconsin, Madison, WI 53706-1580 Contributed by Barry Ganetzky, March 13, 2008 (sent for review December 2, 2007) Although deficiencies in the retromer sorting pathway have been ␥-secretase, it was important to investigate retromer deficiency linked to late-onset Alzheimer’s disease, whether these deficien- on a nonmutated genetic background. To determine whether cies underlie the disease remains unknown. Here we characterized retromer deficiency causes hippocampal dysfunction, a key two genetically modified animal models to test separate but clinical feature of Alzheimer’s disease, we began by investigating related questions about the effects that retromer deficiency has on retromer deficiency in genetically modified mice. Our results the brain. First, testing for cognitive defects, we investigated suggest that retromer deficiency causes hippocampal dysfunction retromer-deficient mice and found that they develop hippocampal- by elevating concentrations of endogenous A␤ peptide. dependent memory and synaptic dysfunction, which was associ- Although APP and BACE are highly homologous across species, ated with elevations in endogenous A␤ peptide. Second, testing important sequence differences do exist, and these differences can for neurodegeneration and amyloid deposits, we investigated affect their intracellular transport, APP processing, and the neu- retromer-deficient flies expressing human wild-type amyloid pre- rotoxicity of APP end products (12).
    [Show full text]
  • Mitochondrial Dynamic Abnormalities in Alzheimer's Disease Sirui Jiang Case Western Reserve University
    MITOCHONDRIAL DYNAMIC ABNORMALITIES IN ALZHEIMER’S DISEASE by SIRUI JIANG Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Dr. Xiongwei Zhu Department of Pathology CASE WESTERN RESERVE UNIVERSITY January 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of SIRUI JIANG Candidate for the degree of Doctor of Philosophy* Dr. Shu Chen (Committee Chair) Dr. Xiongwei Zhu Dr. Xinglong Wang Dr. George Dubyak Dr. Charles Hoppel August 15, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein Table of Contents Table of Contents 1 List of Figures 3 Acknowledgements 5 List of Abbreviations 7 Abstract 10 Chapter 1. Introduction 12 Introduction to Alzheimer’s Disease 13 General Information 13 Pathology 14 Pathogenesis 15 Introduction to Mitochondrial Dynamics 20 Mitochondrial Function and Neuronal Health 20 Mitochondrial Dynamics 21 Mitochondrial Dynamics and Mitochondrial Function 23 Mitochondrial Dynamics and Mitochondrial Transport 24 Mitochondrial Deficits in AD 26 Mitochondrial Dysfunction in AD 26 Aβ and Mitochondrial Dysfunction 27 Mitochondrial Dynamic Abnormalities in AD: Recent Advances 28 Conclusion 34 1 Chapter 2. Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and cortex 36 Abstract 37 Background 39 Methods 43 Results 47 Discussion 54 Figures 60 Chapter 3. DLP1 Cleavage by Calpain in Alzheimer’s Disease 71 Abstract 72 Background 73 Methods 77 Results 80 Discussion 85 Figures 89 Chapter 4. Summary, Discussion and Future Directions 96 References 108 2 List of Figures Figure 2.1 Cre-mediated ablation of Mfn2 expression in the hippocampus and cortex of Mfn2 cKO mice 60 Figure 2.2 Quantification of DLP1 and OPA1 in cKO mice 61 Figure 2.3 Mfn2 ablation caused mitochondrial fragmentation and ultrastructural damage in the hippocampus in vivo as evidenced by electron microscopic analysis.
    [Show full text]
  • Parkinson's Disease-Linked D620N VPS35 Knockin Mice Manifest Tau
    Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration Xi Chena, Jennifer K. Kordicha, Erin T. Williamsa, Nathan Levinea, Allyson Cole-Straussb, Lee Marshalla, Viviane Labriea,c, Jiyan Maa, Jack W. Liptonb, and Darren J. Moorea,1 aCenter for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI 49503; bDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI 49503; and cDivision of Psychiatry and Behavioral Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503 Edited by Anders Björklund, Lund University, Lund, Sweden, and approved February 13, 2019 (received for review August 30, 2018) Mutations in the vacuolar protein sorting 35 ortholog (VPS35) since only a single D620N mutation carrier has been evaluated at gene represent a cause of late-onset, autosomal dominant familial autopsy but with the notable exception of key PD-relevant brain Parkinson’s disease (PD). A single missense mutation, D620N, is regions (i.e., substantia nigra, locus ceruleus, or any brainstem considered pathogenic based upon its segregation with disease area) (7). Outside of these areas, VPS35 mutation carriers lack in multiple families with PD. At present, the mechanism(s) by extranigral α-synuclein–positive Lewy body pathology (7), a which familial VPS35 mutations precipitate neurodegeneration in characteristic hallmark of PD brains. The mechanism by which PD are poorly understood. Here, we employ a germline D620N dominantly inherited mutations in VPS35 induce neuropathology VPS35 knockin (KI) mouse model of PD to formally establish the and neurodegeneration in PD remains enigmatic. age-related pathogenic effects of the D620N mutation at physiolog- VPS35 encodes a core component of the retromer complex, ical expression levels.
    [Show full text]